Hong Zhao

33PUBLICATIONS
24CO-AUTHORS
Molecular targetsPredictive and prognostic markersEpidemiological modellingChemotherapyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Jul 25, 2026
Lenvatinib enhances the response of biliary tract cancer to anti-HER2 therapy.

|Jul 17, 2026
Effectiveness and safety of PD-1/PD-L1 inhibitors plus lenvatinib with or without Gemox chemotherapy in advanced intrahepatic cholangiocarcinoma.

|Feb 12, 2026
Development and validation of prediction model for early allograft dysfunction following liver transplantation based on systematic review and meta-analysis.

Zhihong Zheng, Shuman Kuang, Zipei Wang

|Feb 10, 2026
Efficacy and safety of pembrolizumab, lenvatinib, and reduced-dose gemcitabine/oxaliplatin as initial treatment for advanced biliary tract cancer: a multicenter, single-arm, prospective, phase II study.

Mingjian Piao, Chengjie Li, Shuofeng Li

|Oct 30, 2025
FAD synthase confers ferroptosis resistance and restrains CD8+ T cell recruitment in hepatocellular carcinoma.

Jiashuo Chao, Yuan Liang, Hao Wang

|Oct 28, 2025
Dynamic urinary proteomics integrates single-cell and spatial transcriptomics to reveal tumour microenvironment and predict immunotherapy response in biliary tract cancer.

Shanshan Wang, Zhengguang Guo, Boyu Sun

Pageof 6

Frequent Collaborators

4 joint publications

Xinting Sang

3 joint publications

Lijin Zhao

2 joint publications

Ling Lu

2 joint publications

Jiashuo Chao